Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 3/20 | 0.51 |
| ▸ | TACR1 | P25103 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | REN | P00797 | 4/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1750732 | 1.00 | PDE4B (0.51) | PDE4BTACR1KCNH2SLC6A2SLC6A4 | |
| SCHEMBL2783354 | 0.92 | REN (0.43) | PDE4BTACR1KCNH2RENCYP3A4 | |
| SCHEMBL2783355 | 0.92 | REN (0.43) | PDE4BTACR1KCNH2RENCYP3A4 | |
| SCHEMBL3264631 | 0.91 | KCNH2 (0.47) | PDE4BTACR1KCNH2RENCYP3A4 | |
| SCHEMBL3264633 | 0.91 | KCNH2 (0.47) | PDE4BTACR1KCNH2RENCYP3A4 | |
| SCHEMBL556513 | 0.91 | KCNH2 (0.47) | PDE4BTACR1KCNH2RENCYP3A4 | |
| SCHEMBL1751768 | 0.89 | REN (0.45) | PDE4BTACR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL557592 | 0.86 | PDE4B (0.43) | PDE4BKCNH2RENCYP3A4 | |
| SCHEMBL556676 | 0.85 | GPR119 (0.41) | KCNH2RENCYP3A4 | |
| SCHEMBL2880513 | 0.85 | PDE4B (0.55) | PDE4BTACR1SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8343968-B2 | Case of renin inhibitors | MERCK CANADA INC. (CA) | 2013-01-01 | — | — | US | disclosed |
| US-8076359-B2 | Renin inhibitors | MERCK CANADA INC. (CA) | 2011-12-13 | — | — | US | disclosed |
| US-7968720-B2 | Secondary amines as renin inhibitors | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-06-28 | — | — | US | disclosed |
| US-20100324052-A1 | NOVEL PIPERIDINE CARBOXYLIC ACID AMINE DERIVATIVES | BEZENCON OLIVIER | 2010-12-23 | — | — | US | disclosed |
| US-7799805-B2 | Piperidine carboxylic acid amide derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-09-21 | — | — | US | disclosed |
| EP-2097377-B1 | RENIN INHIBITORS | MERCK FROSST CANADA LTD (CA) | 2010-07-07 | — | — | EP | disclosed |
| US-20100120859-A1 | NOVEL CASE OF RENIN INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2010-05-13 | — | — | US | disclosed |
| EP-2162436-A1 | NOVEL CASE OF RENIN INHIBITORS | Merck Frosst Canada Ltd. (CA) | 2010-03-17 | — | — | EP | disclosed |
| US-20100063091-A1 | RENIN INHIBITORS | MERCK CANADA INC. (CA) | 2010-03-11 | — | — | US | disclosed |
| EP-2097377-A1 | RENIN INHIBITORS | Merck Frosst Canada Ltd. (CA) | 2009-09-09 | — | — | EP | disclosed |
| US-20090176823-A1 | Secondary Amines as Renin Inhibitors | ACTELION PHARMACEUTICALS LTD. (CH) | 2009-07-09 | — | — | US | disclosed |
| WO-2008141462-A9 | NOVEL CASE OF RENIN INHIBITORS | MERCK FROSST CANADA LTD (CA) | 2009-01-08 | — | — | WO | disclosed |
| WO-2008141462-A1 | NOVEL CASE OF RENIN INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2008-11-27 | — | — | WO | disclosed |
| US-20080214598-A1 | Novel Piperidine Carboxylic Acid Amide Derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2008-09-04 | — | — | US | disclosed |
| WO-2008058387-A1 | RENIN INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2008-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063091-A1 | RENIN INHIBITORS | REN, ACE, AGTR1 | PDE4B 310/4885TACR1 133/4885KCNH2 822/4885 |
| US-20080214598-A1 | Novel Piperidine Carboxylic Acid Amide Derivatives | REN, ACE, AGTR2 | PDE4B 205/4885TACR1 142/4885KCNH2 1032/4885 |
| US-20100120859-A1 | NOVEL CASE OF RENIN INHIBITORS | REN, ACE, AGTR1 | PDE4B 710/4885TACR1 126/4885KCNH2 1085/4885 |
| US-20100324052-A1 | NOVEL PIPERIDINE CARBOXYLIC ACID AMINE DERIVATIVES | REN, ACE, AGTR2 | PDE4B 116/4885TACR1 53/4885KCNH2 923/4885 |
| US-20090176823-A1 | Secondary Amines as Renin Inhibitors | REN, ACE, AGTR1 | PDE4B 139/4885TACR1 44/4885KCNH2 476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.